Dihydrotestosterone, Active Androgen Metabolites, and Related Pathology
January 2003
TLDR Dihydrotestosterone (DHT) and its active metabolites play a key role in various diseases, and the development of 5α-reductase inhibitors can help treat these conditions.
The document "Dihydrotestosterone, Active Androgen Metabolites and Related Pathology" from 2002 discussed the role of Dihydrotestosterone (DHT) and its active metabolites in various pathologies. It highlighted the existence of two genes/two enzymes for Steroid 5α-reductase, an enzyme that plays a crucial role in the conversion of testosterone to DHT. The document also discussed Steroid 5α-reductase type 2 deficiency and its implications. It further explored the connection between benign prostatic hyperplasia and the development of 5α-reductase inhibitors. The document also touched upon other applications of 5α-reductase inhibitors and posed remaining questions in the field for future research.
